Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Jonathan Allan, exercised restricted stock units and acquired common shares. On March 15, 2026, he exercised derivative awards covering 25,475 restricted stock units, each representing one share of common stock, at an exercise price of $0.00 per unit.
These exercises resulted in the acquisition of 25,475 shares of common stock, bringing his directly held common stock position to 37,731 shares following the transactions. Footnotes explain that each RSU converts into one share and that the RSU awards vest in annual installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, contingent on continued service.
Stoke Therapeutics director Arthur A. Levin reported an open-market sale of 605 shares of Common Stock at $36.80 per share on March 13, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025.
After this sale, Levin directly holds 4,237 shares of Stoke Therapeutics common stock and indirectly holds 17,979 shares through the Butler-Levin Revocable Trust, where he serves as trustee.
Stoke Therapeutics is a late-stage RNA medicines company using its proprietary TANGO antisense platform to upregulate protein expression for severe genetic diseases, especially autosomal dominant haploinsufficiencies of the central nervous system and eye.
The lead candidate, zorevunersen (STK-001), targets Dravet syndrome and is in the global Phase 3 EMPEROR trial, aiming to enroll about 150 patients, with pivotal data expected in mid‑2027 and a rolling NDA planned in 2027. Earlier Phase 1/2a and extension studies showed substantial, durable convulsive seizure reductions and improvements in cognition and behavior on top of standard anti‑seizure medicines, with zorevunersen generally well tolerated and holding FDA Breakthrough Therapy Designation.
The second clinical program, STK‑002 for autosomal dominant optic atrophy, is in the Phase 1 OSPREY trial after demonstrating preclinical proof‑of‑concept in restoring OPA1 protein and mitochondrial function. Stoke reports a broad TANGO-driven pipeline, a multijurisdictional patent estate extending into the 2030s–2040s, and major collaborations, including a $60 million upfront deal with Acadia around SYNGAP1 and a $165 million upfront global development and ex‑U.S. commercialization partnership with Biogen for zorevunersen.
Stoke Therapeutics Interim Executive Chair Arthur Tzianabos reported an option exercise and share sale involving the company’s common stock. On March 10, 2026, he exercised stock options to acquire 3,955 shares of common stock at an exercise price of $8.33 per share. The same day, he sold 4,355 common shares at a weighted average price of $40.0033 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on August 15, 2025. Following these transactions, he directly holds 31,339 common shares and retains 118,696 stock options that are fully vested and exercisable and expire on March 19, 2034.
Stoke Therapeutics, Inc. director Adrian R. Krainer reported an open-market sale of 33,243 shares of common stock on March 10, 2026 at a weighted average price of $39.7366 per share. After this transaction, he directly holds 283,302 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, meaning the trades were scheduled in advance rather than timed discretionarily.
Morgan Stanley Smith Barney LLC Executive Financial Services58,769 shares dated 03/10/2026 labeled “Exercise of Stock Options” and 31,739 shares dated 02/13/2024 labeled “Previously Exercised Stock Options.”
The entries are presented as filings of shares to be sold under Rule 144; the excerpt does not state the offering methods, proceeds treatment, or timing beyond the listed dates.
Stoke Therapeutics director Adrian R. Krainer sold 7,229 shares of common stock in an open-market transaction on March 2, 2026 at a weighted average price of $39.6618 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, and he now holds 316,545 shares directly.
Stoke Therapeutics, Inc. reported that its Board of Directors approved a discretionary cash bonus of $697,125 for Chief Executive Officer Ian F. Smith. He did not participate in the company’s 2025 annual bonus program, and this bonus equals his full target annual bonus for that year.
The Board based the award on Stoke’s clinical and financial performance following Smith’s appointment as interim CEO in March 2025 and permanent CEO in October 2025. For the 2025 annual bonus program, the Board determined that corporate goal achievement for the company was 150% of target.